| ²é¿´: 1351 | »Ø¸´: 1 | |||
sun332008½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÖú ϸ°ûÁ÷ʽ¼ì²âÑ»·Ö×Áöϸ°û·½·¨ ÒÑÓÐ1È˲ÎÓë
|
| ÇóÖú ÎÒÏëÇë½Ì ϸ°ûÁ÷ʽ¼ì²âÑ»·Ö×Áöϸ°û¾ßÌåʵÑé·½·¨²½Ö裬ÌṩһÏÂÏà¹ØÕâ·½ÃæµÄÎÄÏ×Ò²ºÃ£¬Ð»Ð»¡£ |
» ²ÂÄãϲ»¶
0854 ¿¼Ñе÷¼Á ÕÐÉúÁË£¡AI ·½Ïò
ÒѾÓÐ14È˻ظ´
328Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸ÖØÇì´óѧ085700×ÊÔ´Óë»·¾³£¬×Ü·Ö308Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÕÐ08¿¼Êýѧ
ÒѾÓÐ14È˻ظ´
Ò»Ö¾Ô¸ÉϺ£½»´óÉúÎïÓëҽҩר˶324·Ö£¬Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0854µç×ÓÐÅÏ¢Çóµ÷¼Á 324
ÒѾÓÐ3È˻ظ´
303Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
336Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
306Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
¹¤¿Æ0856Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Ö×Áöϸ°ûÖÜÆÚÕâÑù¸ÃÔõô°ì
ÒѾÓÐ3È˻ظ´
Á÷ʽϸ°ûѧTÁܰÍϸ°û·ÖÐÍ
ÒѾÓÐ6È˻ظ´
Á÷ʽϸ°ûÒDzâÖ²Îï±¶ÐÔ
ÒѾÓÐ14È˻ظ´
Á÷ʽϸ°ûÒDzâϸ°ûÖÜÆÚ£¬¸÷¸öÖÜÆÚ·å·Ö²»¿ª£¬Ö»ÓÐÒ»¸ö¿í·åÊÇʲôÔÒò£¿Ð»Ð»Ö¸µã£¡£¡
ÒѾÓÐ9È˻ظ´
Á÷ʽϸ°ûÒDzⶨϸ°ûµòÍö½á¹û·ÖÎö
ÒѾÓÐ32È˻ظ´
ÇëÎÊÁ÷ʽϸ°ûʵÑéÖÐPIȾҺÖмÓÈëèÛéÚËáÄÆ£¨¼´ÄûÃÊËáÄÆ£©ÓÐʲô×÷ÓÃ~~
ÒѾÓÐ7È˻ظ´
ÇóÖúCFSE±ê¼Ç¼ì²âϸ°ûÔöÖ³
ÒѾÓÐ12È˻ظ´
ÇóÁ÷ʽϸ°ûÒÇ Èí¼þ
ÒѾÓÐ7È˻ظ´
²âROSÊÇ·ñÐèÒª¹Ì¶¨Ï¸°û
ÒѾÓÐ7È˻ظ´
Á÷ʽϸ°ûÊõÏê½â 22Õ½Ú
ÒѾÓÐ185È˻ظ´
ÓÃÁ÷ʽϸ°ûÒǼì²âСÊó¹ÇËèϸ°ûÖÜÆÚ£¬Çó¹ÇËèϸ°û¹Ì¶¨²½Öè
ÒѾÓÐ4È˻ظ´
¡¾½Ì³Ì¡¿Á÷ʽϸ°ûÒDZ걾µÄÖÆ±¸
ÒѾÓÐ93È˻ظ´
ÎÒÏÖÔÚÒª²¹×öÒ»¸öÖ×ÁöÄÍҩʵÑ飬ÐèÒªÓÃʲô·½·¨£¿
ÒѾÓÐ14È˻ظ´
¸ßÊÖ°ïÖú·ÖÎöÒ»ÏÂÁ÷ʽϸ°ûÒÇ˫Ⱦ²âϸ°ûµòÍöµÄÎÊÌâ³öÔÚÄÄ£¿
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿Á÷ʽϸ°ûÒÇÊǸÉʲôÓõÄ
ÒѾÓÐ20È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿Á÷ʽ ϸ°ûÊýÁ¿ÎÊÌâ
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿Á÷ʽϸ°ûÒÇϸ°ûµòÍöÑо¿·½Ãæ
ÒѾÓÐ15È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿Ï¸°ûµòÍöÂʵIJⶨÄܲ»Äܲ»ÓÃÁ÷ʽϸ°ûÒDz⣿
ÒѾÓÐ7È˻ظ´

wotaoyan
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 28
- Ìû×Ó: 4
- ÔÚÏß: 7.2Сʱ
- ³æºÅ: 7408536
- ×¢²á: 2017-11-01
- רҵ: ¿¹Ö×ÁöÒ©ÎïÒ©Àí
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
´ÓÎÄÏ×Öи´ÖƵģ¬Ï£Íû¶ÔÄãÓаïÖú£¬²Î¿¼ÎÄÏ×£ºCetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC)£¬Am J Cancer Res 2018;8(5):879-891 Peripheral blood (7 mL) was obtained from patients on day 1 and day 90 for the detection of CTC levels. MNCs from peripheral blood were separated using LymphoprepTM (Haoyang Biologicals) density gradient centrifugation from buffy coats and were washed twice with sterile Hank¡¯s balanced salt solution (Life Technologies, Carlsbad, CA, USA). Isolated cells were enriched via binding to magnetic CD326 (EpCAM) MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany) using magnetic activated cell sorting. Then, enriched isolated cells were labelled with monoclonal antibodies targeting the epithelial cell antigens CD45, CD326 as well as cytokeratins 8, 18 and 19 (Miltenyi Biotech) and incubated in the dark for 12 min at room temperature. The monoclonal antibodies (10 ¦ÌL) anti-CD45-PE, Ep-CAM-APC,and cytokeratins 8, 18, and 19-FITC were added per 7.5 mL of whole blood. Cell pellets were resuspended in 500 ¦ÌL PBS and enumerated by a FACSCantoTM II (Becton Dickinson, Franklin Lakes, NJ, USA) flow cytometer with a CD45-/CK+/CD326+ gating strategy. The absolute number of CD45-, CK+, and CD326+ cells on FACSCantoTM II was used to measure CTC levels ¡£ |
2Â¥2020-03-29 15:56:10













»Ø¸´´ËÂ¥